News Center

Discover all of the trending news of the Ipsen Group


145 results

Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition…

ILC 2022: Let’s talk PBC

The International Liver Congress (ILC)1 provides a key opportunity for us to meet and…

A message from CEO David Loew

Hear what CEO David Loew has to say about our H1 2022 results. [video width="800"…

Celebrating a decade of The Ixcellence Network®: Supporting ...

By Andreas Lysandropoulos MD, PhD, Vice President Head Global Medical Affairs Neuroscience at Ipsen …

Business

How to transform the medical organization in specialty care ...

By Steven Hildemann, MD, PhD, EVP, Chiel Medical Officer Medical affairs play a central role…

Ipsen publishes strong Q1 2022 results

Ipsen is pleased to announce a strong first-quarter total-sales performance. Total sales, excluding Consumer HealthCare,…

People

Ukraine situation: What Ipsen is doing

Latest Update: March 29, 2022 The on-going tragedy in Ukraine is profoundly worrying, and our…

Financial information

Ipsen presents strong full-year 2021 results and enters into...

Ipsen is pleased to announce its strong 2021 financial performance with total-sales growth of 12.3%…

Group

Our pledge: summaries in plain language for all journal publ...

By Will Gattrell Today, we are broadening our commitment to providing everyone with the opportunity…

Group

Ipsen has been certified by Eurocompliance to the ISO 37001 ...

On the 15th of December 2021, Ipsen has been certified by Eurocompliance to the ISO…

Business

Statement on lanreotide in the U.S.

PARIS, FRANCE, 20 December 2021 - 6:00 PM CET - Ipsen has learned that Cipla…

Business

Ipsen continues to strengthen early oncology pipeline with Q...

Today we are pleased to announce a partnership with the Queen’s University of Belfast (QUB),…

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022